Skye Bioscience, Inc.
SKYE
$1.86
$0.042.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.22% | -14.20% | 11.87% | -20.66% | -37.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.33% | 26.16% | 21.97% | -10.54% | -26.17% |
| Operating Income | -123.33% | -26.16% | -21.97% | 10.54% | 26.17% |
| Income Before Tax | 29.45% | 50.75% | -98.56% | -73.58% | -93.28% |
| Income Tax Expenses | 180.56% | 94.23% | 94.23% | -16.42% | -46.27% |
| Earnings from Continuing Operations | 29.43% | 50.74% | -98.55% | -73.55% | -93.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.43% | 50.74% | -98.55% | -73.55% | -93.23% |
| EBIT | -123.33% | -26.16% | -21.97% | 10.54% | 26.17% |
| EBITDA | -123.17% | -26.21% | -22.19% | 10.59% | 26.38% |
| EPS Basic | 87.22% | 90.35% | 45.15% | 44.03% | 30.61% |
| Normalized Basic EPS | 68.25% | 82.82% | 80.04% | 74.80% | 69.56% |
| EPS Diluted | 87.21% | 90.35% | 45.12% | 48.93% | 42.75% |
| Normalized Diluted EPS | 68.25% | 82.82% | 80.04% | 74.80% | 69.56% |
| Average Basic Shares Outstanding | 420.68% | 538.35% | 591.68% | 388.99% | 214.44% |
| Average Diluted Shares Outstanding | 420.68% | 538.35% | 591.68% | 388.99% | 214.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |